Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ranolazine placebo Clear all
Completed Not applicable Interventional Results available

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

NCT01342029
View directory record Official record
Conditions
Microvascular Coronary Dysfunction (MCD)
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

NCT01163721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Escondido, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 29, 2026, 5:22 PM EDT
Not listed Phase 4 Interventional

Safety of Amiodarone and Ranolazine Together in Patients With Angina

NCT01558830
View directory record Official record
Conditions
Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation, Ventricular Tachycardia
Interventions
ranolazine, placebo
Drug
Lead sponsor
Cardiovascular Consultants of Nevada
Other
Eligibility
35 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Henderson, Nevada • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Sep 29, 2026, 5:22 PM EDT
Not listed Phase 4 Interventional

Effect of Ranolazine on Valvular Disease in Patients With Pacemakers

NCT01979965
View directory record Official record
Conditions
Ischemic Mitral Regurgitation
Interventions
Ranolazine (Active drug), Placebo
Drug
Lead sponsor
University Cardiology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Ranolazine Cardioprotection in PCI

NCT01767987
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Harvey Hahn
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406
View directory record Official record
Conditions
Stable Angina, Metabolic Syndrome
Interventions
Ranolazine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 3 Interventional Results available

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

NCT01352416
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 1 Interventional

A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension

NCT01757808
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 72 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 4 Interventional

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

NCT02156336
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Horizons International Peripheral Group
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Fairhope, Alabama • Houma, Louisiana • Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NCT01425359
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Ranolazine, Ranolazine placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 29, 2026, 5:22 PM EDT
Not listed Phase 4 Interventional

Study to Reduce Symptoms of Premature Beats With Ranolazine

NCT01996618
View directory record Official record
Conditions
Premature Ventricular Beats
Interventions
Ranolazine
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Phase 2 Interventional

A Study of Ranolazine in ALS

NCT06527222
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Swathy Chandrashekhar, MBBS
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Fairway, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Targeting Right Ventricle in Pulmonary Hypertension Gilead

NCT02829034
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

NCT02239926
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
2,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Not applicable Interventional Results available

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

NCT01590979
View directory record Official record
Conditions
Atrial Fibrillation New Onset, Hemorrhage, Prolonged QTc Interval, Ventricular Tachycardia, Medical Care; Complications, Late Effect of Complications
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

NCT01505179
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 29, 2026, 5:22 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

NCT02423265
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Disease, Arteriosclerosis, Chronic Stable Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
East Carolina University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 29, 2026, 5:22 PM EDT
Withdrawn Phase 4 Interventional

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

NCT00657514
View directory record Official record
Conditions
Peripheral Arterial Disease, Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Sep 29, 2026, 5:22 PM EDT
Not listed Phase 4 Interventional

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)

NCT03044964
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Amit Malhotra, MD
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Southaven, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 29, 2026, 5:22 PM EDT